Dr. Gupta is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
111 E 210th St
Bronx, NY 10467Phone+1 718-405-1700Fax+1 207-621-6102
Education & Training
- Medical University of South CarolinaFellowship, Hematology and Medical Oncology, 2017
- Westchester Medical CenterResidency, Internal Medicine, 2011 - 2014
- Maulana Azad Medical CollegeClass of 2010
Certifications & Licensure
- NY State Medical License 2023 - 2025
- ME State Medical License 2018 - 2023
- CA State Medical License 2017 - 2020
- SC State Medical License 2014 - 2017
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Efficacy of hedgehog pathway inhibitors as adjuvant in treating steroid-refractory sclerodermatous chronic graft-versus-host disease.Andres Mendez-Hernandez, Ridhi Gupta, Sally Arai, Robert Lowsky, Bernice Kwong
Journal of the American Academy of Dermatology. 2025-01-21 - A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.Mendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, Yogen Saunthararajah, Kira Gritsman
Blood. 2024-11-28 - 24 citationsOverall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.Robert F. Cornell, Parameswaran Hari, Shijie Tang, Noa Biran, Natalie S. Callander
American Journal of Hematology. 2021-01-01
Lectures
- Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Hedgehog Pathway Inhibitor for Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: